Price
CHART BY
Frequently asked questions
What is Nurix's market capitalization?
The market capitalization of Nurix is $2.39B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Nurix?
Nurix's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$3.447. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Nurix's stock?
Currently, 14 analysts cover Nurix's stock, with a consensus target price of $33.93. Analyst ratings provide insights into the stock's expected performance.
What is Nurix's revenue over the trailing twelve months?
Over the trailing twelve months, Nurix reported a revenue of $36.77M.
What is the EBITDA for Nurix?
Nurix's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$343.92M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Nurix?
Nurix has a free cash flow of -$304.53M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Nurix have, and what sector and industry does it belong to?
Nurix employs approximately 317 people. It operates in the Health Care sector, specifically within the Biotechnology industry.
What is the free float of Nurix's shares?
The free float of Nurix is 98.84M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $2.39B
- EPS (TTM)
- -$3.447
- Free Float
- 98.84M
- Revenue (TTM)
- $36.77M
- EBITDA (TTM)
- -$343.92M
- Free Cashflow (TTM)
- -$304.53M
Pricing
- 52W span
- $9.01$28.18
Analyst Ratings
The price target is $33.93 and the stock is covered by 14 analysts.
Buy
13
Hold
1
Sell
0
Information
Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company. It engages in the business of discovering, developing, and commercializing innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. The company was founded by John Kuriyan, Michael Rapé, and Arthur Weiss in 2009 and is headquartered in Brisbane, CA.
- Employees
- 317
- Industries
- Biotechnology
- Sector
- Health Care
Identifier
- Primary Ticker
- NRIX
Fundamentals & EOD data from FactSet